Fate Therapeutics, Inc.
FATE
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Fate Therapeutics develops and manufactures cell therapies for cancer treatment using induced pluripotent stem cell (iPSC) technology. This process inherently requires animal testing for preclinical research and development, as the company must evaluate the safety and efficacy of its therapeutic candidates in animal models before advancing to human clinical trials. The company's business model is built on this biomedical research pathway.
The specific evidence provided from Cruelty Free Investors and a 2016 inspection report indicates the company maintained an animal research facility. A USDA inspection of its California site in January 2016 found no animal-welfare violations but noted "no animals present," suggesting the facility's use for animal research was intermittent or had ceased at that specific inspection moment. The broader context is that biopharmaceutical companies like Fate Therapeutics operating in cell therapy routinely utilize animal models, including mice and other species, as a standard, required component of the drug development process.
Fate Therapeutics is a clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer and autoimmune disorders. The company's drug development pipeline, from preclinical research through clinical trials, inherently requires animal testing to satisfy regulatory requirements for safety and efficacy. This testing is conducted according to Good Laboratory Practices (GLPs) and is explicitly referenced in the company's SEC filings as part of its standard nonclinical development process.
The biopharmaceutical industry, including companies like Fate Therapeutics, relies on animal models to advance cellular therapies into human trials. While the company's direct animal welfare record shows no cited violations in available inspections, its business model is fundamentally built on a research pathway that commissions and depends on animal testing. As a developer of novel biologic drugs, Fate Therapeutics falls under the exclusion criteria for companies that require animal testing as part of product development and regulatory compliance.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.